CONDITION AND RESULTS OF OPERATIONS AMOUNTS IN THOUSANDS EXCEPT PER SHARE AMOUNTS OR AS OTHERWISE INDICATED RESULTS OF OPERATIONS Three Months Ended September 30 Nine Months Ended September 30 2018 2017 2018 2017 Net sales 100.0 100.0 100.0 100.0 Cost sales exclusive depreciation amortization shown 65.4 65.3 65.2 64.7 Selling research development administrative 15.5 15.3 15.5 15.8 Depreciation amortization 6.3 6.4 5.9 6.2 Restructuring initiatives 3.6 2.3 Operating income 9.2 13.0 11.1 13.3 Other expense 1.5 1.9 1.1 1.4 Income income taxes 7.7 11.1 10.0 11.9 Net Income 5.9 8.6 7.4 9.3 Effective tax rate 23.4 23.0 25.6 22.0 Adjusted EBITDA margin 1 20.2 18.9 19.7 19.4 1 Adjusted EBITDA margins calculated Adjusted EBITDA divided Reported Net Sales See reconciliation non-U.S GAAP measures starting page 38 NET SALES We reported net sales 665.8 million quarter ended September 30 2018 represents 7 increase compared 624.3 million reported third quarter 2017 The average U.S dollar exchange rate strengthened compared major currencies resulting negative currency translation impact 3 The acquisitions CSP Technologies Reboul positively impacted sales 3 Therefore core sales exclude acquisitions changes foreign currency rates increased 7 third quarter 2018 compared third quarter 2017 The core sales growth reflected increased demand products across three reporting segments Core tooling sales increased 0.9 million quarter ended September 30 2018 compared prior year increased sales Beauty Home segment offset lower tooling sales Pharma Food Beverage segments Third Quarter 2018 Beauty Food Net Sales Change Prior Year Home Pharma Beverage Total Core Sales Growth 5 12 4 7 Acquisitions 1 5 4 3 Currency Effects 1 4 3 2 3 Total Reported Net Sales Growth 2 14 6 7 1 Currency effects calculated translating last year amounts year foreign exchange rates For first nine months 2018 reported net sales 2.1 billion 13 first nine months 2017 reported net sales 1.8 billion The average U.S dollar exchange rate weakened compared euro impact several major currencies business mixed This resulted positive currency translation impact 3 Sales also positively impacted 1 acquisitions CSP Technologies Reboul Therefore core sales first nine months 2018 increased 9 three segments reported strong growth first nine months 2017 Core sales also positively impacted higher tooling sales 14.5 million first nine months 2018 compared prior year mainly due increased tooling sales Beauty Home Food Beverage segments 31 Table Contents First Nine Months 2018 Beauty Food Net Sales Change Prior Year Home Pharma Beverage Total Core Sales Growth 8 11 6 9 Acquisitions 1 2 1 Currency Effects 1 3 5 2 3 Total Reported Net Sales Growth 11 17 10 13 1 Currency effects calculated translating last year amounts year foreign exchange rates The following table sets forth periods indicated net sales geographic location Three Months Ended September 30 Nine Months Ended September 30 2018 Total 2017 Total 2018 Total 2017 Total Domestic 181,349 27 164,345 26 528,210 25 484,984 26 Europe 381,472 57 350,631 56 1,232,943 59 1,057,841 57 Latin America 58,294 9 65,557 11 182,810 9 176,965 10 Asia 44,660 7 43,793 7 135,770 7 123,598 7 For discussion net sales reporting segment please refer analysis segment net sales segment Adjusted EBITDA following pages COST OF SALES EXCLUSIVE OF DEPRECIATION AND AMORTIZATION SHOWN BELOW Our cost sales COS percent net sales 65.4 third quarter 2018 nearly equal 65.3 third quarter 2017 While mix product sales favored higher margin Pharma products overall COS percentage negatively impacted higher material costs During quarter experienced increases several raw material substrates principally resin metal While majority material cost increases passed along customers selling prices experience lag timing passing cost increases The incremental business CSP Technologies acquisition also reported higher COS percentage due effects purchase accounting adjustments related inventory negatively impacted overall COS percentage Cost sales percent net sales increased 65.2 first nine months 2018 compared 64.7 period year ago As mentioned COS percentage negatively impacted timing delay resin pass-throughs customers along material increases We also higher COS percentage due mix sales Historically tooling sales margins lower product sales margins Therefore increase tooling sales first nine months 2018 negatively impacted COS percentage We also reported higher COS percentage related operational inefficiencies including start-up costs French anodizing facility along negative impact purchase accounting adjustments related CSP Technologies Reboul acquisitions first nine months 2018 compared first nine months 2017 SELLING RESEARCH DEVELOPMENT AND ADMINISTRATIVE Our selling research development administrative expenses SG&A increased approximately 8.0 million 103.6 million third quarter 2018 compared 95.5 million period 2017 Excluding changes foreign currency rates SG&A increased approximately 10.1 million quarter The increase mainly due 7.1 million one-time transaction costs 1.9 million operational costs related CSP Technologies acquisition third quarter 2018 We also recognized increases professional fees higher personnel costs accordance growth strategy SG&A percentage net sales increased slightly 15.5 compared 15.3 period prior year due acquisition costs cost increases mentioned SG&A increased 30.8 million 323.1 million first nine months 2018 compared 292.3 million period year ago Excluding changes foreign currency rates SG&A increased approximately 21.1 million first nine months 2018 compared first nine months 2017 As discussed increase related 9.5 million one-time acquisition-related costs 1.9 million operational cost related CSP Technologies acquisition along higher professional fees personnel costs related growth strategy During 2018 also recognized approximately 0.9 million costs related write-down administrative building held sale 2017 recognized 1.5 million estimated costs remediate environmental contamination found Company facility Brazil Although SG&A increased amount SG&A percentage net sales decreased 15.5 compared 15.8 period prior year due strong increase sales 32 Table Contents DEPRECIATION AND AMORTIZATION Reported depreciation amortization expenses increased approximately 1.8 million 41.9 million third quarter 2018 compared 40.1 million period year ago Excluding changes foreign currency rates depreciation amortization increased approximately 2.5 million quarter compared period year ago This increase mainly due 2.1 million incremental operational results amortization purchase accounting adjustments related CSP Technologies acquisition We also realized increased capital spending past year support growth business Depreciation amortization percentage net sales decreased 6.3 third quarter 2018 compared 6.4 period prior year primarily due strong increase sales For first nine months 2018 reported depreciation amortization expenses increased approximately 8.4 million 123.1 million compared 114.7 million first nine months 2017 Excluding changes foreign currency rates depreciation amortization increased approximately 4.0 million compared period year ago As discussed increase mainly due 2.1 million incremental costs related CSP Technologies acquisition increased capital spending current year support growth business Depreciation amortization percentage net sales decreased 5.9 first nine months 2018 compared 6.2 period prior year primarily due strong increase sales RESTRUCTURING INITIATIVES In late 2017 Aptar began business transformation drive profitable sales growth increase operational excellence enhance approach innovation improve organizational effectiveness The primary focus plan Beauty Home segment however certain global general administrative functions also addressed During third quarter 2018 recognized approximately 23.9 million restructuring costs related plan approximately 18.9 million 2.0 million 2.6 million 0.4 million reported within Beauty Home segment Pharma segment Food Beverage segment Corporate Other respectively During first nine months 2018 recognized approximately 48.0 million restructuring costs related plan approximately 38.5 million 3.6 million 4.3 million 1.6 million reported within Beauty Home segment Pharma segment Food Beverage segment Corporate Other respectively We estimate total implementation costs approximately 90 million next three years including costs recognized date We also anticipate making capital investments related business transformation approximately 54 million 2018 We expect business transformation yield annualized incremental EBITDA approximately 80 million end 2020 principally within Beauty Home segment OPERATING INCOME Operating income decreased approximately 19.8 million third quarter 2018 compared period year ago Excluding changes foreign currency rates operating income decreased approximately 17.5 million quarter compared period year ago This decrease due 23.9 million restructuring costs 7.1 million transaction costs related CSP Technologies acquisition partially offset increase profitability higher sales third quarter 2018 Operating income percentage net sales decreased 9.2 third quarter 2018 compared 13.0 period prior year due strategic investments For first nine months 2018 operating income decreased approximately 14.3 million 230.0 million compared 244.3 million period prior year Excluding changes foreign currency rates operating income decreased approximately 25.5 million first nine months 2018 compared period year ago As discussed decrease due 48.0 million restructuring costs 9.5 million transaction costs related CSP Technologies Reboul acquisitions partially offset increased profitability higher sales reported first nine months 2018 Operating income percentage net sales decreased 11.1 first nine months 2018 compared 13.3 period prior year mainly due costs NET OTHER EXPENSE Net expense third quarter 2018 decreased 1.2 million 10.2 million 11.4 million period prior year For 2018 interest expense decreased approximately 1.0 million mainly due prepayment two higher interest private placement facilities fourth quarter 2017 cash available repatriation foreign earnings U.S third quarter 2017 Net expenses nine months ended September 30 2018 decreased 2.8 million 23.0 million 25.8 million period prior year This decrease mainly due 4.2 million higher interest income 2018 U.S cash balances repatriated Europe However 2017 realized 2.5 million income forward exchange contracts due forward points currencies invested 33 Table Contents EFFECTIVE TAX RATE The reported effective tax rate three months ended September 30 2018 23.4 The tax rate favorably impacted 4.5 million tax benefits employee share-based compensation along 1.9 million benefit Tax Cuts Jobs Act TCJA provisional items 3.5 million refunds settlement tax claims These favorable items partially offset quarter 1.4 million impact foreign valuation allowances 1.5 million new U.S tax provisions including global intangible low-taxed income GILTI base erosion anti-abuse tax BEAT tax 4.0 million discrete non-discrete tax items The reported effective tax rate three months ended September 30 2017 23.0 The prior year tax rate favorably impacted 4.4 million benefit refunds settlement tax claims The reported effective tax rate nine months ended September 30 2018 25.6 The tax rate favorably impacted 9.9 million tax benefits employee share-based compensation along 5.4 million benefit TCJA provisional items 3.9 million refunds settlement tax claims These favorable items partially offset 6.3 million impact new U.S tax provisions including GILTI BEAT 4.5 million discrete non-discrete tax items The reported effective tax rate nine months ended September 30 2017 22.0 The prior year tax rate favorably impacted 8.8 million tax benefits employee share-based compensation 3.4 million net benefit settlement tax claims 3.6 million benefit repatriation activities U.S NET INCOME ATTRIBUTABLE TO APTARGROUP INC We reported net income attributable AptarGroup 39.0 million 154.1 million three nine months ended September 30 2018 respectively compared 53.5 million 170.5 million periods prior year BEAUTY HOME SEGMENT Operations sell dispensing systems sealing solutions primarily personal care beauty home care markets form Beauty Home segment Three Months Ended September 30 Nine Months Ended September 30 2018 2017 2018 2017 Net Sales 341,760 333,748 1,088,469 978,313 Adjusted EBITDA (1 42,174 42,627 141,155 129,265 Adjusted EBITDA margin (1 12.3 12.8 13.0 13.2 1 Adjusted EBITDA calculated earnings net interest taxes depreciation amortization unallocated corporate expenses restructuring acquisition-related costs Adjusted EBITDA margins calculated Adjusted EBITDA divided Reported Net Sales See reconciliation non-U.S GAAP measures starting page 38 Net sales quarter ended September 30 2018 increased 2 341.8 million compared 333.7 million third quarter prior year Incremental sales Reboul acquisition positively impacted sales 1 changes currency rates negatively impacted net sales 4 Therefore core sales increased 5 third quarter 2018 compared quarter prior year Geographically core sales increased regions compared prior year quarter We experienced strong core sales growth 6 personal care beauty markets core home care sales declined 2 compared prior year due lower custom tooling sales The increase personal care sales mainly relates increased sales products used body care applications increased tooling sales Increased sales beauty market mainly related increased demand facial skin care dispensing solutions 34 Table Contents Third Quarter 2018 Personal Home Net Sales Change Prior Year Care Beauty Care Total Core Sales Growth 6 6 2 5 Acquisitions 2 1 Currency Effects 1 4 4 3 4 Total Reported Net Sales Growth 2 4 5 2 1 Currency effects calculated translating last year amounts year foreign exchange rates Net sales increased 11 first nine months 2018 1.1 billion compared 978.3 million first nine months prior year Changes currency rates positively impacted net sales 3 Acquisitions immaterial nine month period ended September 30 2018 Therefore core sales increased 8 first nine months 2018 compared period prior year Geographically core sales increased regions compared prior year Core sales higher across three markets personal care beauty home care increased 9 8 1 respectively Strong sales facial skin care body care applications along higher tooling sales responsible increase sales first nine months 2018 compared 2017 First Nine Months 2018 Personal Home Net Sales Change Prior Year Care Beauty Care Total Core Sales Growth 9 8 1 8 Acquisitions 1 Currency Effects 1 2 4 2 3 Total Reported Net Sales Growth 11 13 3 11 1 Currency effects calculated translating last year amounts year foreign exchange rates Adjusted EBITDA third quarter 2018 decreased 1 42.2 million compared 42.6 million reported period prior year Increases product tooling sales operational improvement European custom decorative packaging business offset large increases resin metal costs We also experienced unfavorable currency impact Argentina hyperinflation accounting operating results related Reboul acquisition third quarter 2018 Adjusted EBITDA first nine months 2018 increased 9 141.2 million compared 129.3 million reported period prior year Our increase sales compensated increased resin metal costs The first nine months 2017 also included 1.5 million estimated costs remediate environmental contamination found Company anodizing facility Brazil PHARMA SEGMENT Operations sell dispensing systems sealing active packaging solutions primarily prescription drug consumer health care injectables markets form Pharma segment Three Months Ended September 30 Nine Months Ended September 30 2018 2017 2018 2017 Net Sales 227,515 199,547 698,851 598,161 Adjusted EBITDA (1 84,516 66,260 250,709 204,750 Adjusted EBITDA margin (1 37.1 33.2 35.9 34.2 1 Adjusted EBITDA calculated earnings net interest taxes depreciation amortization unallocated corporate expenses restructuring acquisition-related costs Adjusted EBITDA margins calculated Adjusted EBITDA divided Reported Net Sales See reconciliation non-U.S GAAP measures starting page 38 35 Table Contents Net sales Pharma segment increased 14 third quarter 2018 227.5 million compared 199.5 million third quarter 2017 Changes currency negatively affected net sales 3 acquisition CSP Technologies positively impacted sales 5 third quarter 2018 Therefore core sales increased 12 third quarter 2018 compared third quarter 2017 All three existing markets reported increased core sales prior year Core sales prescription market particularly strong increased 15 mainly driven increased demand innovative nasal drug delivery systems central nervous system allergic rhinitis treatments compensated lower tooling sales Sales consumer health care market increased 9 strong demand ophthalmic dermal treatments For injectables market core sales increased 7 primarily due increased demand components used administration antithrombotic products customers Europe third quarter 2018 Third Quarter 2018 Prescription Consumer Active Net Sales Change Prior Year Drug Health Care Injectables Packaging Total Core Sales Growth 15 9 7 12 Acquisitions 100 5 Currency Effects 1 2 4 1 3 Total Reported Net Sales Growth 13 5 6 100 14 1 Currency effects calculated translating last year amounts year foreign exchange rates Net sales first nine months 2018 increased 17 698.9 million compared 598.2 million first nine months 2017 Changes currency rates positively impacted net sales 5 first nine months 2018 CSP Technologies acquisition contributed 1 sales improvement Therefore core sales increased 11 first nine months 2018 compared period prior year As discussed prescription drug market reported core sales increase 10 strong sales products sold central nervous system allergic rhinitis treatments Core sales consumer health care market increased 15 strong demand products used decongestants nasal salines Core sales products injectables markets increased 6 due strong sales injectable components used vaccine products Lower core tooling sales prescription consumer health care negatively impacted segment reported sales 2.5 million first nine months 2018 compared 2017 First Nine Months 2018 Prescription Consumer Active Net Sales Change Prior Year Drug Health Care Injectables Packaging Total Core Sales Growth 10 15 6 11 Acquisitions 100 1 Currency Effects 1 5 3 6 5 Total Reported Net Sales Growth 15 18 12 100 17 1 Currency effects calculated translating last year amounts year foreign exchange rates Adjusted EBITDA third quarter 2018 increased 28 84.5 million compared 66.3 million reported period prior year The strong product sales across three markets discussed along improved operational efficiencies led increase reported results third quarter 2018 compared third quarter 2017 Adjusted EBITDA first nine months 2018 increased 22 250.7 million compared 204.8 million reported period prior year The increased sales improved operational efficiencies discussed offset lower profitability tooling projects 36 Table Contents FOOD BEVERAGE SEGMENT Operations sell dispensing systems sealing solutions primarily food beverage markets form Food Beverage segment Three Months Ended September 30 Nine Months Ended September 30 2018 2017 2018 2017 Net Sales 96,500 91,031 292,413 266,914 Adjusted EBITDA (1 15,482 18,116 46,284 49,756 Adjusted EBITDA margin (1 16.0 19.9 15.8 18.6 1 Adjusted EBITDA calculated earnings net interest taxes depreciation amortization unallocated corporate expenses restructuring acquisition-related costs Adjusted EBITDA margins calculated Adjusted EBITDA divided Reported Net Sales See reconciliation non-U.S GAAP measures starting page 38 Net sales quarter ended September 30 2018 increased approximately 6 96.5 million compared 91.0 million third quarter prior year Incremental sales CSP Technologies acquisition positively impacted sales 4 changes foreign currency rates unfavorable impact 2 total segment sales Therefore core sales increased 4 third quarter 2018 compared third quarter 2017 Core sales food market increased 14 core sales beverage market decreased 8 third quarter 2018 compared period prior year For food market recognized strong sales products infant nutrition customers along higher tooling sales compared period last year For beverage market increase product sales mainly bottled water juice customers offset lower tooling sales drove lower core sales growth third quarter 2018 compared prior year period For segment lower tooling sales 1.0 million compensated 2.2 million increase pass-through resin price changes quarter ended September 30 2018 compared third quarter prior year Third Quarter 2018 Net Sales Change Prior Year Food Beverage Total Core Sales Growth 14 8 4 Acquisitions 5 4 Currency Effects 1 2 2 2 Total Reported Net Sales Growth 17 10 6 1 Currency effects calculated translating last year amounts year foreign exchange rates Net sales first nine months 2018 increased 10 292.4 million compared 266.9 million first nine months 2017 Changes currency rates CSP Technologies acquisition positively impacted net sales 2 first nine months 2018 Therefore core sales increased 6 first nine months 2018 compared period prior year Core sales food market increased 11 core sales beverage market flat compared first nine months 2017 Sales food market increased due strong sales products infant nutrition complemented strong increases tooling sales For beverage market strong sales bottled water juice customers offset decrease tooling sales functional drink application sales mainly China For segment sales first nine months 2018 favorably impacted 7.6 million higher core tooling sales along 6.0 million increase pass-through resin price changes compared first nine months 2017 First Nine Months 2018 Net Sales Change Prior Year Food Beverage Total Core Sales Growth 11 6 Acquisitions 2 2 Currency Effects 1 1 3 2 Total Reported Net Sales Growth 14 3 10 1 Currency effects calculated translating last year amounts year foreign exchange rates Adjusted EBITDA third quarter 2018 decreased 15 15.5 million compared 18.1 million reported period prior year This decrease mainly due significant material cost increases along lower profit tooling projects third quarter 2018 compared third quarter 2017 37 Table Contents Adjusted EBITDA first nine months 2018 decreased 7 46.3 million compared 49.8 million reported period prior year As discussed profitability negatively impacted material cost increases lower tooling profits along price concessions secure long-term supply contracts CORPORATE OTHER In addition three reporting segments Aptar assigns certain costs Corporate Other presented separately Note 15 Segment Information Notes Condensed Consolidated Financial Statements For Corporate Other Adjusted EBITDA excludes net interest taxes depreciation amortization restructuring transaction costs primarily includes certain professional fees compensation information system costs allocated directly reporting segments For quarter ended September 30 2018 Corporate Other expenses decreased slightly 8.0 million 8.8 million Corporate Other expenses first nine months 2018 increased 28.6 million compared 26.9 million reported period prior year This increase mainly due increases advisory legal personnel costs We also reported 0.9 million loss write-down administrative building held sale 2018 NON-U.S GAAP MEASURES In addition information presented herein conforms U.S GAAP also present financial information conform U.S GAAP referred non-U.S GAAP financial measures Management may assess financial results U.S GAAP basis non-U.S GAAP basis We believe useful present non-U.S GAAP financial measures allow better period period comparison operating results removing impact items management view reflect Aptar core operating performance These non-U.S GAAP financial measures considered isolation substitute U.S GAAP financial results read conjunction unaudited condensed consolidated statements income information presented herein Investors cautioned placing undue reliance non-U.S GAAP measures Further investors urged review consider carefully adjustments made management directly comparable U.S GAAP financial measure arrive non-U.S GAAP financial measures In Management Discussion Analysis exclude impact foreign currency translation presenting net sales information define constant currency Changes net sales excluding impact foreign currency translation non-U.S GAAP financial measure As worldwide business important take account effects foreign currency translation view results plan strategies Consequently management looks financial results measure core performance business may exclude impact foreign currency translation translating prior period results current period foreign currency exchange rates As result management believes presentations useful internally may useful investors We also exclude impact material acquisitions comparing results prior periods Changes operating results excluding impact acquisitions non-U.S GAAP financial measures We believe important exclude impact acquisitions period period results order evaluate performance comparable basis We present earnings net interest taxes EBIT earnings net interest taxes depreciation amortization EBITDA We also present adjusted earnings net interest taxes Adjusted EBIT consolidated adjusted earnings net interest taxes depreciation amortization Adjusted EBITDA exclude business transformation charges acquisition-related costs Our Outlook also provided non-U.S GAAP basis certain reconciling items dependent future events either cannot controlled tax exchange rates reliably predicted part Company's routine activities restructuring acquisition-related costs Finally provide reconciliation Net Debt Net Capital non-U.S GAAP measure Net Debt calculated interest bearing debt less cash cash equivalents short-term investments Net Capital calculated stockholder equity plus Net Debt Net Debt Net Capital measures company financial leverage gives users idea company's financial structure financing operations along insight financial strength We believe meaningful take consideration balance cash cash equivalents short-term investments evaluating leverage If needed assets could used reduce gross debt position 38 Table Contents Three Months Ended September 30 2018 Consolidated Beauty Home Pharma Food Beverage Corporate Other Net Interest Net Sales 665,775 341,760 227,515 96,500 Reported net income 39,022 Reported income taxes 11,920 Reported income income taxes 50,942 3,471 67,016 5,481 17,828 7,198 Adjustments Restructuring initiatives 23,852 18,854 2,008 2,638 352 Transaction costs related acquisitions 7,082 7,082 Purchase accounting adjustments related acquired companies inventory 3,287 2,761 526 Adjusted earnings income taxes 85,163 22,325 71,785 8,645 10,394 7,198 Interest expense 8,735 8,735 Interest income 1,537 1,537 Adjusted earnings net interest taxes Adjusted EBIT 92,361 22,325 71,785 8,645 10,394 Depreciation amortization 41,857 19,849 12,731 6,837 2,440 Adjusted earnings net interest taxes depreciation amortization Adjusted EBITDA 134,218 42,174 84,516 15,482 7,954 Adjusted EBITDA margins Adjusted EBITDA Reported Net Sales 20.2 12.3 37.1 16.0 Three Months Ended September 30 2017 Consolidated Beauty Home Pharma Food Beverage Corporate Other Net Interest Net Sales 624,326 333,748 199,547 91,031 Reported net income 53,529 Reported income taxes 15,989 Reported income income taxes 69,518 21,837 55,426 11,668 10,793 8,620 Adjustments None Earnings income taxes 69,518 21,837 55,426 11,668 10,793 8,620 Interest expense 9,733 9,733 Interest income 1,113 1,113 Earnings net interest taxes EBIT 78,138 21,837 55,426 11,668 10,793 Depreciation amortization 40,087 20,790 10,834 6,448 2,015 Earnings net interest taxes depreciation amortization EBITDA 118,225 42,627 66,260 18,116 8,778 EBITDA margins EBITDA Reported Net Sales 18.9 12.8 33.2 19.9 39 Table Contents Nine Months Ended September 30 2018 Consolidated Beauty Home Pharma Food Beverage Corporate Other Net Interest Net Sales 2,079,733 1,088,469 698,851 292,413 Reported net income 154,091 Reported income taxes 52,966 Reported income income taxes 207,057 40,688 208,915 21,736 45,834 18,448 Adjustments Restructuring initiatives 48,002 38,501 3,596 4,307 1,598 Transaction costs related acquisitions 9,526 574 8,952 Purchase accounting adjustments related acquired companies inventory 3,406 119 2,761 526 Adjusted earnings income taxes 267,991 79,882 215,272 26,569 35,284 18,448 Interest expense 24,754 24,754 Interest income 6,306 6,306 Adjusted earnings net interest taxes Adjusted EBIT 286,439 79,882 215,272 26,569 35,284 Depreciation amortization 123,133 61,273 35,437 19,715 6,708 Adjusted earnings net interest taxes depreciation amortization Adjusted EBITDA 409,572 141,155 250,709 46,284 28,576 Adjusted EBITDA margins Adjusted EBITDA Reported Net Sales 19.7 13.0 35.9 15.8 Nine Months Ended September 30 2017 Consolidated Beauty Home Pharma Food Beverage Corporate Other Net Interest Net Sales 1,843,388 978,313 598,161 266,914 Reported net income 170,523 Reported income taxes 48,043 Reported income income taxes 218,566 69,248 174,288 31,385 32,734 23,621 Adjustments None Earnings income taxes 218,566 69,248 174,288 31,385 32,734 23,621 Interest expense 25,707 25,707 Interest income 2,086 2,086 Earnings net interest taxes EBIT 242,187 69,248 174,288 31,385 32,734 Depreciation amortization 114,660 60,017 30,462 18,371 5,810 Earnings net interest taxes depreciation amortization EBITDA 356,847 129,265 204,750 49,756 26,924 EBITDA margins EBITDA Reported Net Sales 19.4 13.2 34.2 18.6 40 Table Contents Net Debt Net Capital Reconciliation September 30 December 31 2018 2017 Notes payable including revolving credit facilities 153,236 4,336 Current maturities long-term obligations net unamortized debt issuance costs 64,039 61,833 Long-Term Obligations net unamortized debt issuance costs 1,131,737 1,191,146 Total Debt 1,349,012 1,257,315 Less Cash equivalents 291,382 712,640 Net Debt 1,057,630 544,675 Total Stockholders Equity 1,392,058 1,312,048 Net Debt 1,057,630 544,675 Net Capital 2,449,688 1,856,723 Net Debt Net Capital 43.2 29.3 FOREIGN CURRENCY Because international presence movements exchange rates may significant impact translation financial statements foreign subsidiaries Our primary foreign exchange exposure euro also foreign exchange exposure Chinese yuan Brazilian real Mexican peso Swiss franc Asian European South American currencies A strengthening U.S dollar relative foreign currencies dilutive translation effect financial statements Conversely weakening U.S dollar additive effect In cases sell products denominated currency different currency related costs incurred We manage exposures foreign exchange principally forward exchange contracts economically hedge recorded transactions firm purchase sales commitments denominated foreign currencies Changes exchange rates inter-country sales could materially impact results operations During third quarter 2018 U.S dollar strengthened compared Euro This resulted dilutive impact translated results third quarter 2018 compared third quarter 2017 Beginning July 1 2018 applied highly inflationary accounting Argentinian subsidiaries We changed functional currency Argentinian peso U.S dollar Our Argentinian operations contributed approximately 2.0 consolidated net assets revenues nine months ended September 30 2018 QUARTERLY TRENDS Our results operations last quarter year typically negatively impacted customer plant shutdowns December In future results operations quarterly period could impacted factors seasonality certain products within segments changes foreign currency rates changes product mix changes material costs changes growth rates markets products sold recognition equity-based compensation expense retirement eligible employees period grant changes general economic conditions countries business We generally incur higher employee stock option expense first quarter compared rest fiscal year Our estimated total stock-based compensation expense pre-tax basis millions year 2018 compared 2017 follows 2018 2017 First Quarter 7.5 7.8 Second Quarter 3.4 3.9 Third Quarter 3.9 3.3 Fourth Quarter estimated 2018 4.7 3.9 19.5 18.9 41 Table Contents LIQUIDITY AND CAPITAL RESOURCES We believe strong financial position financial resources meet business requirements foreseeable future We historically used cash flow operations revolving credit facilities stock option exercises debt needed primary sources liquidity Our primary uses liquidity invest equipment facilities necessary support growth make acquisitions contribute achievement strategic objectives Other uses liquidity include repurchasing shares common stock paying dividends stockholders On October 18 2018 Board Directors declared quarterly cash dividend 0.34 per share payable November 21 2018 stockholders record October 31 2018 In event customer demand would decrease significantly prolonged period time negatively impact cash flow operations would ability restrict significantly reduce capital expenditure levels well evaluate acquisition strategy dividend share repurchase programs A prolonged significant reduction capital expenditure levels could increase future repairs maintenance costs well negative impact operating margins unable invest new innovative products During 2017 voluntarily repatriated approximately 1.0 billion Europe U.S This achieved combination surplus available cash raising debt UK subsidiary Europe This gave us full financial flexibility utilize repatriated cash meet U.S funding needs strategic business investments including recent acquisition CSP Technologies Adding euro-denominated debt better aligns capital structure euro earnings base able take advantage historically low euro debt interest rates At September 30 2018 weighted-average debt interest rate 2.66 mix fixed floating debt 90:10 Cash equivalents decreased 291.4 million September 30 2018 712.6 million December 31 2017 primarily due acquisition CSP Technologies Total short long-term interest bearing debt 1.3 billion September 30 2018 level December 31 2017 Due decrease cash fund CSP Technologies acquisition ratio Net Debt interest bearing debt less cash cash equivalents Net Capital stockholders equity plus Net Debt increased 43.2 September 30 2018 compared 29.3 December 31 2017 See reconciliation non-U.S GAAP measures starting page 38 In first nine months 2018 operations provided approximately 209.6 million net cash flow compared 265.2 million period year ago In periods cash flow operations primarily derived earnings depreciation amortization The decrease cash provided operations primarily attributable decrease net income business transformation expenses We used 668.7 million cash investing activities first nine months 2018 compared 189.2 million period year ago Approximately 553.5 million cash exclusive 24.1 million cash acquired utilized fund acquisition CSP Technologies 2018 5.0 million currently held restricted cash pending finalization working capital adjustment expected completed within 75 days closing We also invested 10.0 million preferred equity stock Reciprocal Labs Corporation business Propeller Health accounted cost acquired Reboul French manufacturer specializing stamping decorating assembling metal plastic packaging cosmetics luxury markets initial purchase price approximately 3.6 million exclusive 112 thousand cash acquired Our investment capital projects increased 24.5 million first nine months 2018 compared first nine months 2017 support growth business Our 2018 estimated cash outlays capital expenditures expected range approximately 190 210 million could vary due changes exchange rates well timing capital projects The increase cash used investing activities first nine months 2018 partially offset receipt 10.6 million insurance proceeds related Annecy fire property damages In 2017 also invested 5.0 million 20 minority investment technology company provides digital monitoring systems medical devices Financing activities provided 50.3 million cash first nine months 2018 compared 447.3 million period year ago During first nine months 2018 received net proceeds short term credit facility stock option exercises 139.4 million 78.9 million respectively We used cash hand repay 67.0 million long-term debt pay 61.0 million dividends repurchase 61.7 million common stock Following repatriation 2017 1.0 billion Europe U.S funds used repay 160 million outstanding U.S revolving credit facility repurchase 113.3 million common stock 42 Table Contents On July 20 2017 Company replaced 300 million revolving credit facility new 5-year multi-currency revolving credit facility two tranches providing unsecured financing 300 million available U.S 150 million available wholly-owned UK subsidiary Each borrowing credit facility bear interest rates based LIBOR prime rates similar rates case plus applicable margin A facility fee total amount facility also payable quarterly regardless usage The applicable margins borrowings credit facility facility fee percentage may change time time depending changes Aptar consolidated leverage ratio We utilized 35.0 million U.S credit facility 89.5 million UK subsidiary credit facility September 30 2018 outstanding balance December 31 2017 We incurred approximately 850 thousand 734 thousand interest fees related credit facilities nine months ended September 30 2018 2017 respectively Our revolving credit facility corporate long-term obligations require us satisfy certain financial covenants including Requirement Level September 30 2018 Consolidated Leverage Ratio 1 Maximum 3.50 1.00 2.05 1.00 Consolidated Interest Coverage Ratio 1 Minimum 3.00 1.00 12.36 1.00 1 Definitions ratios included part revolving credit facility agreement private placement agreements Based upon consolidated leverage ratio covenant ability borrow approximately additional 773 million 3.50 1.00 maximum ratio requirement exceeded Our foreign operations historically met cash requirements use internally generated cash uncommitted short-term borrowings We also committed financing arrangements U.S UK detailed We manage global cash requirements considering available funds among many subsidiaries conduct business ii geographic location liquidity needs iii cost access international cash balances During third quarter 2017 Company entered borrowing arrangements summarized wholly-owned UK subsidiary better balance capital structure Debt type Amount Term/Maturity Interest rate Bank term loan 280 million 5 year amortizing/July 2022 2.56 floating swapped 1.36 fixed Bank revolver 150 million 5 year/July 2022 1.10 floating Private placement 100 million 6 year/July 2023 0.98 fixed Private placement 200 million 7 year/July 2024 1.17 fixed Aptar also entered EUR/USD floating-to-fixed cross currency swap July 20 2017 mitigate currency risk U.S dollar debt euro functional currency entity also mitigate risk variability interest rates 280 million bank term loan The Company expects future European cash flows sufficient service new debt CONTINGENCIES The Company normal course business subject number lawsuits claims actual potential nature Please refer Note 11 Commitments Contingencies Notes Condensed Consolidated Financial Statements discussion contingencies affecting Company business OFF-BALANCE SHEET ARRANGEMENTS We lease certain warehouse plant office facilities well certain equipment noncancelable operating leases expiring various dates year 2027 Most operating leases contain renewal options certain equipment leases include options purchase end lease term Other operating lease obligations off-balance sheet arrangements RECENTLY ISSUED ACCOUNTING STANDARDS We reviewed recently issued accounting standards updates FASB Accounting Standards Codification future effective dates Standards effective 2018 discussed Note 1 Summary Significant Accounting Policies Notes Condensed Consolidated Financial Statements 43 Table Contents In February 2016 FASB issued ASU 2016-02 subsequent amendments requires organizations recognize leases balance sheet disclose key information leasing arrangements The new standard establishes right-of-use ROU model requires lessee recognize ROU asset lease liability balance sheet leases term longer 12 months Leases classified finance operating classification affecting pattern recognition expense income statement The new standard effective fiscal years interim periods beginning December 15 2018 early adoption permitted We expect adopt new standard effective date A modified retrospective transition approach required applying new standard leases existing date initial application An entity may choose use either 1 effective date 2 beginning earliest comparative period presented financial statements date initial application If entity chooses second option transition requirements existing leases also apply leases entered date initial application effective date The entity must also recast comparative period financial statements provide disclosures required new standard comparative periods We expect adopt new standard January 1 2019 use effective date option 1 date initial application Consequently financial information updated disclosures required new standard provided dates periods January 1 2019 The new standard provides number optional practical expedients transition We expect elect package practical expedients permits us reassess new standard prior conclusions lease identification lease classification initial direct costs The new standard also provides practical expedients entity ongoing accounting We currently expect elect short-term lease recognition exemption leases qualify This means leases qualify recognize ROU assets lease liabilities includes recognizing ROU assets lease liabilities existing short-term leases assets transition While continue assess effects adoption currently believe significant effects relate recognition new ROU assets lease liabilities balance sheet operating leases significant new disclosures leasing activities In June 2016 FASB issued ASU 2016-13 changes accounting guidance measurement credit losses financial instruments The guidance replaces incurred loss impairment methodology current U.S GAAP methodology reflects expected credit losses requires consideration broader range reasonable supportable information recording credit loss estimates The new standard effective fiscal years interim periods beginning December 15 2019 The Company currently evaluating impact adopting guidance In January 2017 FASB issued ASU 2017-04 provides guidance simplify entity required test goodwill impairment eliminating Step 2 goodwill impairment test As result impairment charges required amount reporting units carrying amount exceeds fair value amount allocated goodwill The new standard effective annual interim goodwill impairment tests fiscal years beginning December 15 2019 The Company believe new guidance material impact Condensed Consolidated Financial Statements In February 2018 FASB issued ASU 2018-02 provides guidance reclassification certain tax effects accumulated comprehensive income This guidance allows reclassification accumulated comprehensive income retained earnings stranded tax effects resulting TCJA The new standard effective fiscal years interim periods beginning December 15 2018 The Company currently evaluating impact adopting guidance In August 2018 FASB issued ASU 2018-14 amends disclosure requirements defined benefit pension postretirement plans The amendments update remove disclosures longer considered cost beneficial clarify specific requirements disclosures add disclosure requirements identified relevant The new standard effective fiscal years ending December 15 2020 As update amends disclosure requirements Company expect significant impact around adopting guidance In August 2018 FASB issued ASU 2018-15 help entities evaluate accounting fees paid customer cloud computing arrangement hosting arrangement providing guidance determining arrangement includes software license The amendments update align requirements capitalizing implementation costs incurred hosting arrangement service contract requirements capitalizing implementation costs incurred develop obtain internal-use software hosting arrangements include internal-use software license Accordingly amendments require entity customer hosting arrangement service contract follow guidance Subtopic 350-40 determine implementation costs capitalize asset related service contract costs expense The amendments also require entity customer expense capitalized implementation costs hosting arrangement service contract term hosting arrangement includes reasonably certain renewals The new standard effective fiscal years beginning December 15 2019 The Company currently evaluating impact adopting guidance Other accounting standards issued FASB standards-setting bodies require adoption future date expected material impact Condensed Consolidated Financial Statements upon adoption 44 Table Contents OUTLOOK For fourth quarter expect continued core sales growth segment prior year spite difficult comparisons strong prior year fourth quarter segment posted double digit core sales growth However expect inflationary environment continue raw material transportation costs expected weigh margins due normal delay passing increased costs Further anticipate isolated weaker beverage volumes China We expect earnings per share fourth quarter excluding restructuring acquisition costs range 0.81 0.86 This guidance based effective tax rate range 30 32 Prior year reported earnings per share 0.77 included gain insurance recovery 0.11 per share restructuring expenses 0.03 per share 0.12 per share impact tax reform legislation enacted fourth quarter last year Excluding effects adjusting comparable exchange rates positive impact 0.03 per share prior year adjusted earnings per share 0.78 Prior year adjusted earnings per share would approximately 0.07 lower current effective tax rate applied prior year adjusted earnings FORWARD-LOOKING STATEMENTS Certain statements Management Discussion Analysis sections Form 10-Q forward-looking involve number risks uncertainties including certain statements set forth Restructuring Initiatives Quarterly Trends Liquidity Capital Resources Contingencies Outlook sections Form 10-Q Words expects anticipates believes estimates future potential similar expressions future conditional verbs would could intended identify forward-looking statements Forward-looking statements made pursuant safe harbor provisions Section 27A Securities Act 1933 Section 21E Securities Exchange Act 1934 Exchange Act based beliefs well assumptions made information currently available us Accordingly actual results may differ materially expressed implied forward-looking statements due known unknown risks uncertainties exist operations business environment including limited economic conditions worldwide including potential deflationary inflationary conditions regions rely growth political conditions worldwide impact tax reform legislation changes tax rates tax-related events transactions could impact effective tax rate significant fluctuations foreign currency exchange rates financial conditions customers suppliers consolidations within customer supplier bases changes customer and/or consumer spending levels loss one key accounts availability raw materials components particularly sole sourced suppliers well financial viability suppliers fluctuations cost materials components input costs particularly resin metal anodization costs transportation energy costs impact extent contamination found Company facility Brazil ability successfully implement facility expansions new facility projects impact UK leaving European Union Brexit UK operations ability offset inflationary impacts cost containment productivity initiatives price increases changes capital availability cost including interest rate fluctuations volatility global credit markets timing magnitude capital expenditures ability identify potential new acquisitions successfully acquire integrate operations products including successful integration CSP Technologies business direct indirect consequences acts war terrorism social unrest cybersecurity threats could impact networks reporting systems impact natural disasters weather-related occurrences fiscal monetary policies regulations changes difficulties complying government regulation changing regulations market conditions regarding environmental sustainability work stoppages due labor disputes competition including technological advances ability protect defend intellectual property rights well litigation involving intellectual property rights outcome legal proceeding may instituted us others ability meet future cash flow estimates support goodwill impairment testing demand existing new products 45 Table Contents success customers products particularly pharmaceutical industry ability manage worldwide customer launches complex technical products particularly developing markets difficulties product development uncertainties related timing outcome product development significant product liability claims successful execution business transformation risks associated operations Although believe forward-looking statements based reasonable assumptions assurance actual results performance achievements differ materially future results performance achievements expressed implied forward-looking statements Readers cautioned place undue reliance forward-looking statements We undertake obligation update publicly forward-looking statements whether result new information future events otherwise except required law Please refer Item 1A Risk Factors Part I included Company Annual Report Form 10-K year ended December 31 2017 additional risk factors affecting Company 46 Table Contents ITEM 3 QUANTITATIVE AND QUALITATIVE